Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24928
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHafeez, Umbreen-
dc.contributor.authorParslow, Adam C-
dc.contributor.authorGan, Hui K-
dc.contributor.authorScott, Andrew M-
dc.date2020-10-26-
dc.date.accessioned2020-10-02T03:26:53Z-
dc.date.available2020-10-02T03:26:53Z-
dc.date.issued2020-12-
dc.identifier.citationExpert Review of Anticancer Therapy 2020; 20(12): 1057-1074en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/24928-
dc.description.abstractThe importance of ErbB3 receptor tyrosine kinase in cancer progression, primary and acquired drug resistance, has become steadily evident since its discovery in 1989. ErbB3 overexpression in various solid organ malignancies is associated with shorter survival of patients. However, initial strategies to therapeutically target ErbB3 have not been rewarding. Here, we provide an overview of ErbB3 biology in carcinogenesis. We outline the role of ErbB3 as a critical pathway for resistance to other anti-cancer drugs. We focus on emerging clinical data, which will steer the potential future development of ErbB3 directed therapies. Initial approaches to ErbB3 targeting have been challenging. However, the lack of success of anti-ErbB3 therapies in ongoing clinical trials may relate more to the complex biology of the receptor and challenges with the biomarkers used to date. Furthermore, it seems certain that the expression of the receptor per se is necessary but not sufficient for the response to ErbB3 therapies. Emerging data suggest that more sophisticated biomarkers are needed. Nonetheless, it is also likely that ErbB3 therapies may have the most efficacy in combination therapy, and their favorable toxicity profile makes this feasible.en
dc.language.isoeng-
dc.subjectErbB3en
dc.subjectErbB3 amplificationen
dc.subjectErbB3 mutationsen
dc.subjectErbB3 overexpressionen
dc.subjectanti-ErbB3 antibodiesen
dc.subjectanti-ErbB3 therapiesen
dc.subjectmonoclonal antibodiesen
dc.subjectreceptor tyrosine kinaseen
dc.titleNew insights into ErbB3 function and therapeutic targeting in cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne , Melbourne, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University , Melbourne, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.doi10.1080/14737140.2020.1829485en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7963-6367en
dc.identifier.pubmedid32981377-
local.name.researcherGan, Hui K
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.